Drugs / Menopur
Menopur
also known as
Hp-hMG · menotropin · Menotropins · hMG · human menopausal gonadotrophin · human menopausal gonadotrophins · Menopure · Menotrophin · +9 more
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | MENOPUR | — | 2004-10-29 | fda.gov ↗ |
Trials 28 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04902131 | Nov 2021 → Aug 2022 | female infertility | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06997900 | Jul 2025 → Aug 2026 overdue | infertility disorder | Clinique Ovo | Recruiting | No outcome recorded |
| Phase 2 | NCT01732094 | Jul 2012 → May 2013 | infertility disorder, ovarian dysfunction | University Hospital Brussels | Completed | No outcome recorded |
| Phase 2 | NCT01732068 | Jul 2012 → May 2013 | infertility disorder, ovarian dysfunction | University Hospital Brussels | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02237781 | Oct → Dec 2014 | female infertility | University of Athens | Unknown | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT06486870 | Jan 2020 → Jan 2024 | polycystic ovary syndrome | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT04163458 | Oct 2019 → May 2021 | infertility disorder | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02732808 | Sep 2014 → Apr 2016 | female infertility | Royan Institute | Completed | No outcome recorded |
| Phase 3 | NCT01816321 | Mar 2013 → May 2016 | infertility disorder, ovarian dysfunction | University Hospital Brussels | Completed | No outcome recorded |
| Phase 3 | NCT00971152 | Sep 2009 → Oct 2013 | infertility disorder | Clinique Ovo | Completed | No outcome recorded |
| Phase 3 | NCT00884221 | Jul 2009 → Jul 2010 | infertility disorder | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 411 trials | ||||||
| Phase 4 | NCT02554279 | Aug 2015 → Jan 2017 | infertility disorder | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02213627 | Oct 2014 → Sep 2015 | female reproductive system disorder, infertility disorder | IVI Madrid | Unknown | No outcome recorded |
| Phase 4 | NCT02069808 | Apr 2014 → Feb 2017 | — | Michigan Reproductive Medicine | Completed | No outcome recorded |
| Phase 4 | NCT01417195 | Jul 2011 → Jan 2012 | infertility disorder | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01250821 | Dec 2010 → Dec 2012 | anovulation, female infertility | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 4 | NCT01225835 | Oct 2010 → Jan 2013 | female infertility | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00805935 | Jan 2009 → Jul 2010 | infertility disorder, polycystic ovary syndrome | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00802360 | Dec 2008 → Nov 2009 | infertility disorder | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00334425 | Apr 2006 → ? | infertility disorder | Central Jutland Regional Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00257556 | Oct 2005 → Jul 2008 | female infertility | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00829075 | Jan 2005 → Dec 2006 | — | Instituto Valenciano de Infertilidad, IVI VALENCIA | Completed | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT03578172 | Jul 2018 → Oct 2019 | adhesions of uterus, female infertility | Reproductive & Genetic Hospital of CITIC-Xiangya | Completed | No outcome recorded |
| — | NCT03483545 | Jul 2018 → Jul 2019 | infertility disorder | Dr François Bissonnette | Completed | No outcome recorded |
| — | NCT02865681 | Jul 2016 → Jun 2017 | infertility disorder | New Hope Fertility Center | Completed | No outcome recorded |
| — | NCT03098199 | Oct 2015 → Dec 2017 | infertility disorder | Reproductive Specialists of New York | Completed | No outcome recorded |
| — | NCT02418533 | Mar 2015 → Apr 2017 | infertility disorder | Main Line Fertility Center | Completed | No outcome recorded |
| — | NCT01623570 | Mar 2011 → May 2012 | hypogonadotropic hypogonadism | Centro Riproduzione e Andrologia | Completed | No outcome recorded |
Also used as a comparator or background therapy in 26 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02510534 Comparator | Jul 2015 → Apr 2016 | pregnancy disorder | Northwest Center for Infertility and Reproductive Endocrinology | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04071574 Comparator | Feb 2018 → Aug 2019 | ectopic pregnancy, endometriosis, female infertility, hydrosalpinx +6 | Lebanese University | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT02099916 Comparator | Oct → Dec 2014 | ovarian dysfunction | University of Athens | Unknown | No outcome recorded |
| Phase 2/3 | NCT02237755 Comparator | Oct → Nov 2014 | female infertility | University of Athens | Unknown | No outcome recorded |
| Phase 2/3 | NCT01590173 Comparator | Jan 2012 → Jul 2016 | infertility disorder | National and Kapodistrian University of Athens | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT04537078 Comparator | Sep 2020 → Mar 2021 | female infertility | El Shatby University Hospital for Obstetrics and Gynecology | Completed | No outcome recorded |
| Phase 3 | NCT02542280 Background | Jul 2013 → Jul 2015 | infertility disorder | Ain Shams Maternity Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01312766 Comparator | Feb 2011 → Apr 2013 | infertility disorder | IBSA Institut Biochimique SA | Completed | No outcome recorded |
| Phase 410 trials | ||||||
| Phase 4 | NCT04385342 Comparator | Jun 2020 → May 2022 | — | Mansoura University | Unknown | No outcome recorded |
| Phase 4 | NCT03177538 Comparator | Sep 2017 → Nov 2018 | female infertility | D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology | Completed | No outcome recorded |
| Phase 4 | NCT02992808 Comparator | Dec 2016 → Jan 2018 | female infertility | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT02738580 Comparator | Oct 2016 → Jun 2018 | infertility disorder, ovarian hyperstimulation syndrome | Instituto Valenciano de Infertilidad, IVI VALENCIA | Completed | No outcome recorded |
| Phase 4 | NCT03208972 Comparator | Oct 2014 → Nov 2015 | infertility disorder | AZ Jan Palfijn Gent | Completed | No outcome recorded |
| Phase 4 | NCT02458768 Comparator | Jul 2013 → Nov 2014 | female infertility | LG Life Sciences | Completed | No outcome recorded |
| Phase 4 | NCT01577199 Comparator | Apr → Dec 2012 | female infertility | Weill Medical College of Cornell University | Withdrawn | No outcome recorded |
| Phase 4 | NCT01345812 Comparator | Apr 2011 → Jul 2012 | — | University of Aarhus | Terminated | No outcome recorded |
| Phase 4 | NCT01888744 Comparator | Sep 2010 → Jun 2013 | infertility disorder | University Hospital Brussels | Completed | No outcome recorded |
| Phase 4 | NCT00820482 Comparator | Jan → May 2009 | — | Instituto Valenciano de Infertilidad, IVI VALENCIA | Completed | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT04193930 Background | Jan 2021 | — | Assiut University | Withdrawn | No outcome recorded |
| — | NCT03684824 Background | Sep 2018 → Sep 2019 | — | Cairo University | Unknown | No outcome recorded |
| — | NCT04416607 Comparator | Jun 2018 → Jan 2019 | female infertility | Hospital de Clinicas de Porto Alegre | Completed | No outcome recorded |
| — | NCT03737253 Comparator | Sep 2016 → Dec 2021 | female infertility | Lund University | Completed | No outcome recorded |
| — | NCT02128360 Comparator | Mar 2015 → Jun 2016 | infertility disorder | Sheba Medical Center | Unknown | No outcome recorded |
| — | NCT01669291 Comparator | Jul 2012 → May 2014 | infertility disorder | Main Line Fertility Center | Completed | No outcome recorded |
| — | NCT01569945 Comparator | Sep 2004 → Dec 2010 | infertility disorder | University Hospital, Gasthuisberg | Completed | No outcome recorded |
| — | NCT00492934 Comparator | Jan 2004 → Oct 2013 | infertility disorder | University Hospital, Gasthuisberg | Unknown | No outcome recorded |
Evidence & citations 21 cited values
Every value below carries the sentence it was read from. 58 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Menopur | “Furthermore, the MARCS study showed that combining REKOVELLE with highly purified hMG (MENOPUR) led to higher number of retrieved oocytes and improved blastulation rate...” NCT06997900 ↗19“Patients start to inject human menopausal gonadotrophin (HMG) (Menopur®, Ferring, Switzerland) 150 IU every other day beginning on cycle day 6.” NCT02732808 ↗ “and human menopausal gonadotrophin (Menopur; Ferring Pharmaceuticals, Langley, Berkshire, UK) will be used” NCT01590173 ↗ “225 international units of gonadotropins (eg Follistim , Menopur)” NCT01577199 ↗ “Menopur (Highly Purified Human Menopausal Gonadotropin)” NCT03483545 ↗ “Menopur 75IU , Gonal” NCT02237755 ↗ “Menopur 75IU, Gonal” NCT02099916 ↗ “Menopur 600 IU” NCT02213627 ↗ |
| Known as | follicle-stimulating hormone | “The medication used in this study is the follicle-stimulating hormone "highly purified human menopausal gonadotrophin" (HP-HMG), Menopur, (Ferring a/s).” NCT01250821 ↗ |
| Known as | Gonadotropins | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02128360 ↗ |
| Known as | highly purified hMG | “Highly purified hMG is at least as effective as rFSH in GnRH antagonist cycles with compulsory single-blastocyst transfer.” PMID 22244781 ↗ Jan 2012 |
| Known as | highly purified human menopausal gonadotrophin | “The medication used in this study is the follicle-stimulating hormone "highly purified human menopausal gonadotrophin" (HP-HMG), Menopur, (Ferring a/s).” NCT01250821 ↗ |
| Known as | Highly purified menotrophin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00884221 ↗ |
| Known as | highly purified menotropin | “highly purified menotropin (hphMG) and recombinant FSH (rFSH)” PMID 22244781 ↗ Jan 2012 |
| Known as | hMG | “Patients start to inject human menopausal gonadotrophin (HMG) (Menopur®, Ferring, Switzerland) 150 IU every other day beginning on cycle day 6.” NCT02732808 ↗4“Human menopausal gonadotrophin (hMG) is given starting on cycle day three in a dose of 75 IU alternate days.” NCT06486870 ↗ “cycle hormonally stimulated with s.c. gonadotrophins (hMG FET group, 37.5-75 IU per day, n = 288).” PMID 26364081 ↗ Sep 2015 “150-300 IU/day HMG (menotropin, Menopur, Ferring, Brazil) is administered, starting on cycle day 3” NCT04416607 ↗ “Administration of Menotropin (hMG / FSH and LH at a 1:1 ratio) (150-225IU/day)” NCT04071574 ↗ |
| Known as | HMG-HP | “Menopur: HMG-HP (150 IU)” NCT01623570 ↗ |
| Known as | hp-FSH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03208972 ↗ |
| Known as | Hp-hMG | “Does ovarian stimulation with highly purified (hp)-HMG protect from elevated progesterone in the follicular phase compared to recombinant FSH (r-FSH) cycles through a different...” PMID 38037188 ↗ Feb 202414“The medication used in this study is the follicle-stimulating hormone "highly purified human menopausal gonadotrophin" (HP-HMG), Menopur, (Ferring a/s).” NCT01250821 ↗ “highly purified menotropin (hphMG) and recombinant FSH (rFSH)” PMID 22244781 ↗ Jan 2012 “75 UI/day of Hp-hMG (Menopur®)” NCT00820482 ↗ |
| Known as | human menopausal gonadotrophin | “Inducing ovulation by human menopausal gonadotrophin ampoules given intramuscular starting from cycle day two, till the leading follicle reaches 16 - 18 mm.” NCT02542280 ↗3“Patients start to inject human menopausal gonadotrophin (HMG) (Menopur®, Ferring, Switzerland) 150 IU every other day beginning on cycle day 6.” NCT02732808 ↗ “Human menopausal gonadotrophin (hMG) is given starting on cycle day three in a dose of 75 IU alternate days.” NCT06486870 ↗ |
| Known as | human menopausal gonadotrophins | “Controlled ovarian hyperstimulation will be done using daily intramuscular injection of highly purified Human Menopausal Gonadotrophins (Merional 75 IU/ml, IBSA, Switzerland),...” NCT03684824 ↗ |
| Known as | human menopausal gonadotropin | “150-300 IU/day human menopausal gonadotropin (HMG) according to age, antimullerian hormone (AMH) level and antral follicle count (AFC) in group 2” NCT04416607 ↗ |
| Known as | Menopure | “Menopure” NCT04537078 ↗1“Menopure” NCT02237781 ↗ |
| Known as | Menotrophin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00257556 ↗ |
| Known as | menotropin | “150-300 IU/day HMG (menotropin, Menopur, Ferring, Brazil) is administered, starting on cycle day 3” NCT04416607 ↗7“Administration of Menotropin (hMG / FSH and LH at a 1:1 ratio) (150-225IU/day)” NCT04071574 ↗ |
| Known as | Menotropins | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04416607 ↗ |
| Action | Activate | “for stimulation of the ovaries” NCT03737253 ↗ |
| Modality | Protein / enzyme biologic | “highly purified human menopausal gonadotropins (HP-hMG)” PMID 25385669 ↗ Nov 2014 |
| Route | Subcutaneous | “daily subcutaneous injection” NCT00257556 ↗ |